Source comparison
BPC-157 for Patellar Tendinitis Research: Dosing and Safety Comparison
Mechanism Enhances fibroblast migration, upregulates VEGF and collagen I synthesis, modulates NO pathways via GABA-B receptors Inhibits COX enzymes, reduces prostaglandin-mediated inflammation Delivers concentrated growth factors (PDGF, TGF-β, IGF-1) to injury
This comparison does not assign a generated winner or score.
- Mechanism
- Enhances fibroblast migration, upregulates VEGF and collagen I synthesis, modulates NO pathways via GABA-B receptors
- Inhibits COX enzymes, reduces prostaglandin-mediated inflammation
- Delivers concentrated growth factors (PDGF, TGF-β, IGF-1) to injury site via autologous platelets
- BPC-157 targets regenerative pathways NSAIDs don't. But lacks human safety data
- Dosing Protocol
- 10–20 mcg/kg body weight daily (rodent models). No validated human dosing exists
- 400–800 mg oral, 3x daily for 7–14 days
- Single injection of 3–5 mL platelet concentrate, often repeated 2–3 times over 6 weeks
- Rodent-to-human extrapolation is unreliable without pharmacokinetic studies
- Route of Administration
- Subcutaneous injection near injury site or intramuscular in affected limb
- Oral tablet or topical gel
- Ultrasound-guided injection into tendon or peritendinous space
- Local injection may concentrate peptide at injury site. Untested in humans
- Evidence Level
- Preclinical only (rodent/rabbit models). Zero published human trials as of 2026
- Extensive human RCTs. FDA-approved for pain and inflammation
- Mixed human evidence. Some RCTs show benefit, others no difference vs placebo
- PRP and NSAIDs have regulatory approval; BPC-157 does not
- Time to Observed Benefit
- 7–14 days (histological markers in rodents); 28 days (tensile strength recovery)
- 2–6 hours (symptom relief). Does not accelerate healing
- 4–12 weeks (variable patient response)
- BPC-157 targets healing timelines, not acute symptom relief
- Known Risks
- Unknown in humans. Rodent studies report no adverse events at standard doses
- GI bleeding, cardiovascular risk with prolonged use, impairs collagen synthesis
- Infection risk (1–2%), temporary pain increase post-injection, inconsistent preparation quality
- Absence of human toxicity data is a critical knowledge gap